BMSN get in on the Ground Floor, before the Run:
SAN DIEGO, CA--(Marketwired - Dec 11, 2014) - Regen BioPharma Inc. (OTC PINK: RGBP) announced today it presented data demonstrating NR2F6, a new drug target, is essential in development and maintenance of leukemia and myelodysplastic syndrome at the American Society of Hematology Annual Meeting. This new drug target was identified by the Company's senior research consultant, Dr. Christine Ichim. A drug target is a gene involved in a disease which researchers aim to inhibit its function in order to treat the disease. Regen recently acquired intellectual property generated at the University of Toronto for inhibiting NR2F6.
BMSN
